80.
-
Denne gang et fase 3 studie, der forsøger at vippe Arzerra af pinden i den eneste godkendte indikation; 3.line CLL:
A Phase 3 Study of Ibrutinib Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (RESONATE
)
This study is not yet open for participant recruitment.
Verified April 2012 by PharmacyclicsFirst Received on April 11, 2012. Last Updated on April 13, 2012
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind